Addex Therapeutics (ADXN)

Business description

Addex Therapeutics is a Swiss biotech company with a leading position in the identification of allosteric modulators with activity in CNS, inflammatory and metabolic disease. Its pipeline includes two Phase II compounds, with one partnered with J&J.

New orphan disease focus

Outlook | Pharmaceutical & healthcare | 05/03/2013

Addex is now focused on developing its clinical pipeline for rare diseases and will significantly reduce discovery activities. In 2013 Addex will complete a pilot Phase II study of dipraglurant for rare dystonia and target a partnership for the Parkinson’s disease (PD) indication. It will also complete a Phase I study of ADX71441 for Charcot-Marie-Tooth (CMT) disease, as well as select a clinical candidate for the mGlu4 PAM programme in multiple sclerosis. While Addex is currently financed to end-2013, potential licensing deals and/or financings could extend the cash runway.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.CHF32.9m
Last closeCHF2.140
High / Low (52 weeks)CHF2.5 / CHF1.8
Stock market listingSW
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
SectorPharmaceutical & healthcare

Price performance

Relative *(4.8)(8.9)(23.3)

* % Relative to local index